Clario, a software provider for drugmakers, files confidentially for a U.S. IPO, aiming for a valuation exceeding $10 billion. The IPO market sees renewed activity in 2024.
Bollywood Fever: Clario, a leading software provider for the pharmaceutical industry, has confidentially filed for an initial public offering (IPO) in the United States, aiming for a valuation exceeding $10 billion, according to a Bloomberg News report on Tuesday.
The U.S. IPO market has seen a resurgence in 2024 after a nearly two-year hiatus. Optimism around a potential soft landing for the economy has encouraged companies to consider going public.
Clario is collaborating with top-tier underwriters, including JPMorgan Chase & Co., Morgan Stanley, Jefferies Financial Group, and UBS Group AG, as reported by Bloomberg, citing sources familiar with the matter.
The uptick in IPO activity this year reflects growing confidence in economic stability, prompting more companies to list their shares. Clario’s anticipated IPO could mark a significant moment in the ongoing revival of the U.S. IPO market.
Also Read other news articles, Indonesia’s National Data Center Hacked: Government Refuses to Pay $8 Million Ransom
German Government Moves $24.34 Million Worth of Bitcoin to Exchanges, Signaling Potential Sale
Timeline of Microsoft’s EU Antitrust Battles: From Interoperability to Team Bundling Charges